Phase 1/2 study of investigational hypoxia-targeted drug, TH-302, and bevacizumab (bev) in recurrent glioblastoma (GBM) following bev failure.
Andrew Jacob Brenner
No relevant relationships to disclose
Jessica D Sun
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
John Floyd
No relevant relationships to disclose
Charles P Hart
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
Clarence Eng
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
Stew Kroll
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
Lisa Fichtel
No relevant relationships to disclose
Aleksandra Gruslova
No relevant relationships to disclose
Alessia Lodi
No relevant relationships to disclose
Stefano Tiziani
No relevant relationships to disclose